KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Debt to Equity: 2019-2025

Historic Debt to Equity for Rigel Pharmaceuticals (RIGL) over the last 6 years, with Sep 2025 value amounting to $0.51.

  • Rigel Pharmaceuticals' Debt to Equity rose 112.44% to $0.51 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.51, marking a year-over-year increase of 112.44%. This contributed to the annual value of $18.15 for FY2024, which is 972.31% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Debt to Equity of $0.51 as of Q3 2025, which was down 30.43% from $0.73 recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Debt to Equity ranged from a high of $18.15 in Q4 2024 and a low of -$8.11 during Q2 2022.
  • In the last 3 years, Rigel Pharmaceuticals' Debt to Equity had a median value of -$1.88 in 2024 and averaged $0.56.
  • Over the last 5 years, Rigel Pharmaceuticals' Debt to Equity had its largest YoY gain of 1,632.37% in 2022, and its largest YoY loss of 2,882.69% in 2022.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' Debt to Equity stood at $0.66 in 2021, then plummeted by 541.89% to -$2.90 in 2022, then increased by 28.18% to -$2.08 in 2023, then surged by 972.31% to $18.15 in 2024, then surged by 112.44% to $0.51 in 2025.
  • Its Debt to Equity was $0.51 in Q3 2025, compared to $0.73 in Q2 2025 and $3.22 in Q1 2025.